JP Morgan Chase
CODX

JP Morgan Chase’s Co-Diagnostics CODX Stock Holding History

JP Morgan Chase’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,080
Closed -$869K – 5663
2020
Q3 		$869K Buy
+2,080
New +$1.07M ﹤0.01% 3719

Other funds holding CODX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAG
Private Advisory Group Redmond, Washington $1.85B AUM 50.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase's CODX Position: Q2 2026 in Review

JP Morgan Chase reduced its Co-Diagnostics (CODX) stake by 94% in Q2 2026, selling an estimated $145 and leaving 3 shares worth $9. The position accounts for ﹤0.01% of the portfolio, ranked #7652.

JP Morgan Chase first reported a position in CODX in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.19M in Q3 2020. 24 funds tracked by Wall St. Rank hold CODX as of Q2 2026.

  • JP Morgan Chase held 3 shares of Co-Diagnostics worth $9 as of Q2 2026.
  • JP Morgan Chase sold 47 Co-Diagnostics shares in Q2 2026, an estimated $145.
  • Co-Diagnostics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7652 holding.
  • JP Morgan Chase first reported a position in Co-Diagnostics in Q2 2020 and has held it in 25 quarters since.
  • JP Morgan Chase's Co-Diagnostics position peaked at $1.19M in Q3 2020.
  • 24 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.